Saturday, July 2, 2022
News
NEWS HOME
»
PRN INDIA
Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma
  SocialTwist Tell-a-Friend  
   

-- European Commission Decision Anticipated within Approximately 60 Days --

NEWTON, Mass. and FLORENCE, Italy, May 20, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group ("Menarini"), a privately-held, leading international pharmaceutical company, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of NEXPOVIO ® (selinexor), a first-in-class, oral exportin 1 (XPO1) inhibitor, in combination with once weekly bortezomib (Velcade ®) and low-dose dexamethasone (SVd) for the treatment of adults with multiple myeloma who have received one to three prior lines of therapy.

MENARINI Group Logo

The positive CHMP opinion is a scientific recommendation for marketing authorization and one of the final steps before the European Commission (EC) makes a decision on Karyopharm's NEXPOVIO application. The EC's decision is expected within approximately 60 days following the CHMP recommendation. In December 2021,  Karyopharm and Menarini Group entered into an exclusive license agreement to commercialize NEXPOVIO ® (selinexor) in Europe.

"Despite therapeutic advances, multiple myeloma remains an incurable disease that is difficult to treat," said Richard Paulson, President and Chief Executive Officer of Karyopharm. "Today's positive CHMP opinion brings us one step closer to our goal of making NEXPOVIO available to patients globally who may benefit from its novel mechanism of action. We are pleased to have Menarini as a partner in this effort given its commercialization expertise as well as strong heritage and footprint in Europe."

"We are thrilled with the CHMP's recommendation in favor of NEXPOVIO and what it represents for multiple myeloma patients in need of new and innovative treatment options," said Elcin Barker Ergun, Chief Executive Officer of Menarini. "Pending potential marketing authorization from the EC, we will work closely with appropriate authorities to ensure this important treatment can be made available to patients in Europe."

Karyopharm's application is supported by data from the Phase 3 BOSTON study, which evaluated  the SVd triplet regimen in patients with relapsed or refractory multiple myeloma and were published in The Lancet (Grosicki, et al.) in November 2020. This CHMP opinion follows the approval of XPOVIO ® (selinexor) by the U.S. Food and Drug Administration in December 2020 in the SVd combination in patients with multiple myeloma after at least one prior therapy.

About the Pivotal Phase 3 BOSTON Study

The Phase 3 BOSTON (Bortezomib, Selinexor and Dexamethasone) study was an multi-center, randomized study (NCT03110562), which evaluated 402 adult patients with relapsed or refractory multiple myeloma who had received one to three prior lines of therapy. The study was designed to compare the efficacy, safety and certain health-related quality of life parameters of once-weekly SVd versus twice-weekly bortezomib and low-dose dexamethasone (Vd). The primary endpoint of the study was progression-free survival (PFS) and key secondary endpoints included overall response rate (ORR), rate of peripheral neuropathy, and others. Additionally, the BOSTON study allowed for patients on the Vd control arm to crossover to the SVd arm following objective (quantitative) progression of disease verified by an Independent Review Committee (IRC). The BOSTON study was conducted at over 150 clinical sites internationally.

Despite the study having a high proportion of patients with high-risk cytogenetics (~50%) compared to other Velcade ®-based studies in previously treated myeloma, the median PFS in the SVd arm was 13.93 months compared to 9.46 months in the Vd arm, representing a 4.47 month (47%) increase in median PFS (hazard ratio (HR)=0.70; p=0.0075). The SVd arm also demonstrated a significantly greater ORR compared to the Vd arm (76.4% vs. 62.3%, p=0.0012). Patients who had received only one prior line of therapy also demonstrated a higher ORR on the SVd arm as compared to the Vd arm (80.8% vs. 65.7%, p=0.0082). Importantly, SVd therapy compared to Vd therapy showed consistent PFS benefit and higher ORR across several important subgroups.

In addition, the following results favored SVd therapy as compared to Vd therapy:

  • SVd therapy demonstrated a significantly higher rate of deep responses, defined as ≥ Very Good Partial Response compared to Vd therapy (44.6% vs. 32.4%) as well as a longer median duration of response (20.3 months vs. 12.9 months). Additionally, 16.9% of patients on the SVd arm achieved a complete response or a stringent complete response as compared to 10.6% of patients receiving Vd therapy.   All responses were confirmed by an IRC.
  • Data as of the cut-off date of February 15, 2021 showed a trend toward an overall survival (OS) benefit associated with SVd therapy with fewer deaths, numerically, reported on the SVd arm (68 vs. 80). Median OS for the SVd arm was 36.7 months, while the median OS for the Vd arm was 32.8 months.
  • Peripheral neuropathy (PN) rates were significantly lower on SVd compared to Vd (32.3% vs. 47.1%; p=0.0010). In addition, PN rates of grade ≥2 were also significantly lower in the SVd arm compared to Vd (21.0% vs. 34.3%, P=0.0013).

The most common adverse events (AEs; ≥20%) were cytopenias, along with gastrointestinal and constitutional symptoms and were consistent with those previously reported from other selinexor studies. Most AEs were manageable with dose modifications and/or standard supportive care. The most common non-hematologic AEs were fatigue (59%), nausea (50%), decreased appetite (35%), diarrhea (32%), peripheral neuropathy (32%), upper respiratory tract infection (29%), decreased weight (26%), cataract (22%) and vomiting (21%) and were mostly Grade 1 and 2 events. The most common Grade 3 and 4 AEs (≥10%) were thrombocytopenia, lymphopenia, hypophosphatemia, anemia, hyponatremia and neutropenia.

About Multiple Myeloma in Europe

Multiple myeloma is an incurable cancer with significant morbidity and the second most common hematologic malignancy. According to the World Health Organization, in 2020, there were approximately 51,000 new cases and 32,000 deaths from multiple myeloma in Europe1. While the treatment of multiple myeloma has improved over the last 20 years, and overall survival has increased considerably, the disease remains incurable, and nearly all patients will eventually relapse and develop disease that is refractory to all approved anti-myeloma therapies. Therefore, there continues to be a high unmet medical need for new therapies, particularly those with novel mechanisms of action.

About NEXPOVIO ® (selinexor)

NEXPOVIO, which is marketed as XPOVIO in the U.S., is a first-in-class, oral exportin 1 (XPO1) inhibitor. NEXPOVIO functions by selectively binding to and inhibiting the nuclear export protein exportin 1 (XPO1, also called CRM1). NEXPOVIO blocks the nuclear export of tumor suppressor, growth regulatory and anti-inflammatory proteins, leading to accumulation of these proteins in the nucleus and enhancing their anti-cancer activity in the cell. The forced nuclear retention of these proteins can counteract a multitude of the oncogenic pathways that, unchecked, allow cancer cells with severe DNA damage to continue to grow and divide in an unrestrained fashion. NEXPOVIO has been granted conditional marketing authorization by the European Commission in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Therapeutic indication for NEXPOVIO in the EU Member States as well as Iceland, Liechtenstein, Norway and Northern Ireland.   NEXPOVIO is also approved in the UK under a Conditional Marketing Authorisation.

NEXPOVIO is indicated in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

IMPORTANT SAFETY INFORMATION

Contraindications:  Hypersensitivity to selinexor.

Special warnings and precautions for use:

Recommended concomitant treatments

Patients should be advised to maintain adequate fluid and caloric intake throughout treatment. Intravenous hydration should be considered for patients at risk of dehydration.

Prophylactic concomitant treatment with a 5-HT3 antagonist and/or other anti-nausea agents should be provided prior to and during treatment with NEXPOVIO.

Haematology:

Patients should have their complete blood counts (CBC) assessed at baseline, during treatment, and as clinically indicated. Monitor more frequently during the first two months of treatment.

Thrombocytopenia:

Thrombocytopenic events (thrombocytopenia and platelet count decreased) were frequently reported in adult patients receiving selinexor, which can be severe (Grade 3/4). Patients should be monitored for signs and symptoms of bleeding and evaluated promptly.

Neutropenia:

Severe neutropenia (Grade 3/4) has been reported with selinexor.

Patients with neutropenia should be monitored for signs of infection and evaluated promptly.

Gastrointestinal toxicity:

Nausea, vomiting, diarrhoea, which sometimes can be severe and may require the use of anti-emetic and anti-diarrhoeal medicinal products.

Weight loss and anorexia:

Patients should have their body weight, nutritional status and volume checked at baseline, during treatment, and as clinically indicated. Monitoring should be more frequent during the first two months of treatment.

Confusional state and dizziness:

Patients should be instructed to avoid situations where dizziness or confusional state may be a problem and to not take other medicinal products that may cause dizziness or confusional state without adequate medical advice. Patients should be advised not to drive or operate heavy machinery until symptoms resolve.

Hyponatraemia:

Patients should have their sodium levels checked at baseline, during treatment, and as clinically indicated. Monitoring should be more frequent during the first two months of treatment.

Tumour lysis syndrome (TLS):

TLS has been reported in patients receiving therapy with selinexor. Patients at a high risk for TLS should be monitored closely. Treat TLS promptly in accordance with institutional guidelines.

Fertility, pregnancy and lactation

Women of childbearing potential/contraception in males and females:

Women of childbearing potential and male adult patients of reproductive potential should be advised to use effective contraceptive measures or abstain from sexual intercourse while being treated with selinexor and for at least 1 week following the last dose of selinexor.

Pregnancy:

There are no data from the use of selinexor in pregnant women.   Selinexor is not recommended during pregnancy and in women of childbearing potential not using contraception.

Breast-feeding:

It is unknown whether selinexor or its metabolites are excreted in human milk. A risk to breast-fed children cannot be excluded. Breast-feeding should be discontinued during treatment with selinexor and for 1 week after the last dose.

Undesirable effects

Summary of the safety profile

The most frequent adverse reactions (≥30%) of selinexor in combination with dexamethasone were nausea, thrombocytopenia, fatigue, anaemia, decreased appetite, decreased weight, diarrhea, vomiting, hyponatraemia, neutropenia and leukopenia.

The most commonly reported serious adverse reactions (≥3%) were pneumonia, sepsis, thrombocytopenia, acute kidney injury, and anaemia.

Description of selected adverse reactions

Infections: Infection was the most common non-haematological toxicity. Upper respiratory tract infection and pneumonia were the most commonly reported infections with 25% of reported infections being serious and fatal infections occurring in 3% of treated adult patients.

Elderly population

Patients 75 years and older had a higher incidence of discontinuation due to an adverse reaction, higher incidence of serious adverse reactions, and higher incidence of fatal adverse reactions.

Reporting of suspected adverse reactions

Reporting of suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

Please see NEXPOVIO Summary of Product Characteristics and European Public Assessment Report at https://ec.europa.eu/health/documents/community-register/html/h1537.htm

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: nuclear export dysregulation. Karyopharm's lead SINE compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO ® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications and has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO ®), China and Singapore. Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in endometrial cancer, myelodysplastic syndromes and myelofibrosis. For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on Twitter at @Karyopharm  and LinkedIn.

About Menarini Group

The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of over $4 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for oncology, cardiology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia. With 18 production sites and 9 Research and Development centers, Menarini's products are available in 140 countries worldwide.

Menarini has a deep commitment for developing treatments addressing oncological and hematologic diseases. Menarini actively develops Elzonris (marketed in US and Europe for BPDCN) for multiple hematologic malignancies, including AML, CMML and myelofibrosis, and elacestrant and felezenexor for oncology as well. Additionally, the FDA recently granted MEN1703 an orphan drug designation for AML. For further information, please visit www.menarini.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the potential approval and commercial launch of NEXPOVIO in the European Union[Europe]; the  ability of selinexor to treat patients with multiple myeloma; and expectations related to future clinical development and potential regulatory submissions of selinexor.   Such statements are subject to numerous important factors, risks and uncertainties, many of which are beyond Karyopharm's control, that may cause actual events or results to differ materially from Karyopharm's current expectations. For example, there can be no guarantee that Karyopharm will successfully commercialize XPOVIO or that any of Karyopharm's drug candidates, including selinexor and eltanexor, will successfully complete necessary clinical development phases or that development of any of Karyopharm's drug candidates will continue. Further, there can be no guarantee that any positive developments in the development or commercialization of Karyopharm's drug candidate portfolio will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: the risk that the COVID-19 pandemic could disrupt Karyopharm's business more severely than it currently anticipates, including by negatively impacting sales of XPOVIO, interrupting or delaying research and development efforts, impacting the ability to procure sufficient supply for the development and commercialization of selinexor or other product candidates, delaying ongoing or planned clinical trials, impeding the execution of business plans, planned regulatory milestones and timelines, or inconveniencing patients; the adoption of XPOVIO in the commercial marketplace, the timing and costs involved in commercializing XPOVIO or any of Karyopharm's drug candidates that receive regulatory approval; the ability to obtain and retain regulatory approval of XPOVIO or any of Karyopharm's drug candidates that receive regulatory approval; Karyopharm's results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies, including with respect to the need for additional clinical studies; the ability of Karyopharm or its third party collaborators or successors in interest to fully perform their respective obligations under the applicable agreement and the potential future financial implications of such agreement; Karyopharm's ability to enroll patients in its clinical trials; unplanned cash requirements and expenditures; development or regulatory approval of drug candidates by Karyopharm's competitors for products or product candidates in which Karyopharm is currently commercializing or developing; and Karyopharm's ability to obtain, maintain and enforce patent and other intellectual property protection for any of its products or product candidates. These and other risks are described under the caption "Risk Factors" in Karyopharm's Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, which was filed with the Securities and Exchange Commission (SEC) on May 5, 2022, and in other filings that Karyopharm may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by law, Karyopharm expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

References

1 World Health Organization. 2020. https://gco.iarc.fr/today/data/factsheets/cancers/35-Multiple-myeloma-fact-sheet.pdf

Logo- https://mma.prnewswire.com/media/652491/MENARINI_Group_Logo.jpg

 

More News by PR Newswire India

CGTN: Hong Kong, an East-West culture bridge

CGTN: Hong Kong to start a new chapter after 25 years of prosperity

Harsh Shah joins Azure Power as Chief Executive Officer

TUMI enters official partnership with Tottenham Hotspur

IMG Partners with eMed to Provide Telehealth Proctored COVID-19 Tests to Groups of International Travelers

Petal Maps turns navigation into an immersive and realistic experience

2022 GAC Tech Day Brings a New Wave of Technology

With $2M seed funding, Overtune aim to democratize music creation

CCTV+: New Hong Kong chief executive sworn in

Xinhua Silk Road: Kelan Cashmere Goat Price Index released in N. China's Shanxi

Antaisolar launches new BIPV product, propels zero-carbon transformation of buildings

CGTN: Hong Kong youths embrace brighter future as city integrates into national development

Diageo Reserve to Host the World Class Cocktail Festival in Mumbai: Consumers to Experience a Whole New World of Cocktail Culture

BASF & Permionics join hands to launch high performance face masks

MARATHON DU MONT-BLANC, MORE THAN 2,000 RUNNERS ON THE SLOPES OF EUROPE'S HIGHEST PEAK

CWT launches 'Nashe Se Azadi' anti-drug abuse campaign in collaboration with NCB & Chandigarh Police

GoCardless to acquire open banking platform Nordigen, combining broad open banking connectivity with bank payment expertise

Social network Zorro rebrands as Hood ahead of its US launch

BITS Pilani WILP's MBA in Digital Business to Help Working Professionals Transform Businesses Comprehensively

Yahsat Announces Appointment of Sulaiman Al Ali as Chief Commercial Officer of Yahsat to Drive Next Phase of YahClick and Thuraya Growth

CGTN: 'One Country, Two Systems' ensures Hong Kong's prosperity, stability

Petal Search celebrates incredible growth on its 2nd Anniversary

CGTN: Hong Kong 25 years on: A cultural bond between China and the world

AORUS ELITE is the best go-to motherboard for upgrade

Lummus Digital partners with LACC to develop AI powered Remote Performance Monitoring for Ethane Cracker Unit

Startek® Recognized Among India's Best Companies to Work For 2022 by Great Place to Work® Institute

Ribbon Wins TIA QuEST Forum Sustainability Award for Excellence in Network Equipment Sustainability

Orange Health, India's Fastest Diagnostic Lab launches in New Delhi

Floraxis Media Group announces winners of the National Dental Service Leadership Award, 2022

Neuromod Publishes Results of Second Large Scale Clinical Trial for Tinnitus in Top-Tier Scientific Journal, Shows Greater Improvement of Symptoms

Leading Electric Vehicle Market, GWM ORA Officially Unveiled at the EVS35 in Norway

Tata AIA Life Is Proud To Support AIA On The ONE BILLION Movement

Xinhua Silk Road: 2022 World Canal Cities Forum held in Yangzhou, east China

'Mera Shehar, Sunder Shehar' campaign on environment protection launched by Chandigarh Welfare Trust along with Chandigarh Tourism

ROCKWOOL, a leading Danish mineral wool products manufacturer that helps address challenges of modern living in a sustainable manner launches its first Customer Experience Center in Dahej, Gujarat, India

ELLE FANNING - THE AMBASSADOR OF FAME, PACO RABANNE'S NEW FEMININE FRAGRANCE

Cashfree Payments' tokenization solution 'Token Vault' introduces interoperability across payment gateways

Odisha Investors' Meet, Dubai: CM Naveen Highlights Vast Investment Opportunities In Odisha - IPICOL

Strayos Inc., USA, and Squadrone Infra & Mining Pvt. Ltd., Bangalore, India, are announcing a new partnership

Global Metrology Software Market Driven by High Demand for Quality Control

Clarivate Top 100 New Brands Report Reveals Trends and Hotspots in Rapidly Evolving Global Brand Landscape

Frontier introduces support for Calm Radio, Klassik Radio Select, Bluetooth 5.0 and the latest version of Spotify Connect

Gaming Laboratories International (GLI®) GLI Africa Reaches Landmark Milestone with 100 Employees

Absen reaches an historic milestone of signing 1000 global channel partners

LiveHire to Sponsor Webinar with Global Workforce Management and announces availability of its Total Talent Acquisition and Direct Sourcing Platform in India

Alex Bentley buys $40k worth property in LootMogul Metaverse

BE OPEN celebrates winners of DESIGN TO NURTURE THE PLANET, competition to support the UN sustainable goals

Embark on A Personalised Search Journey with Petal Search

PureSoftware creates a bridge to get "Back to Work®" for Female Professionals on Career Break

MOËT HENNESSY STRENGTHENS ITS GLOBAL PORTFOLIO OF EXCEPTIONAL WINES WITH THE ACQUISITION OF JOSEPH PHELPS VINEYARDS, ONE OF THE MOST RESPECTED AND ACCLAIMED WINE PROPERTIES OF THE NAPA VALLEY IN CALIFORNIA

Israel Honors Pfizer CEO Albert Bourla with the "Jewish Nobel" Prize

Eurofins DiscoverX Celebrates Shanghai Office Opening

ViewSonic Partners With New Taipei City to Build the World's First Citywide Education Metaverse

Warwick consolidates Mayfair collection with Green Street portfolio addition

Clinch Partners with IAS to Launch Industry-Leading Automated Tag Wrapping Solution

Fair Fund to Compensate Certain Investors in Facebook, Inc., Common Stock.

#PrideMonth: 8 LGBTQIA Key Opinion Leaders (KOLs) Making Big International Impact

Deltek Once Again Recognized by G2 as a Project-Based ERP Leader

Permanent art display in monumental desert set to become global icon

Insurance providers can assess customer health risks in real-time using contactless vital sign monitoring solution from NuraLogix

Xinhua Silk Road: Conference to recruit talents in dire need held in Wangcheng District of Changsha in central China

Global Infrastructure Partners and ADIA Agree to Acquire 72.55% Interest in European Rail Logistics Company, VTG

International and Domestic manufacturers and exporters from 15 countries to showcase latest in apparel, textile and fashion industry innovations at ASW 2022

New Report Ranks OMD Worldwide #1 Media Agency as Marketers Shift Focus from Navigating Disruption to Managing Transformation

BioLineRx Enters Co-Development Agreement with GenFleet to Further Develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC), Advised by MSQ Ventures

TheMathCompany Launches AI Xecutive Council

LyondellBasell Announces Renewable Energy Power Purchase Agreements

/C O R R E C T I O N -- PokerStars/

QS reveals the world's best cities for students

PLDT triples international capacity with US-Transpacific Jupiter Cable PH link

CGTN: Hong Kong 25 years on: A bigger role in nation's opening-up

National Inbound and Domestic Tourism Association of Moldova (ANTRIM) launches the documentary film: "A Small Country with a Big Heart"

ABB Applauded by Frost & Sullivan for Decreasing Power Consumption and Lowering Carbon Emissions with Its Power Technology Subsea System

DBN Group Jointly Tackle Down Pressing Agricultural Problems with Top-notch Scientist and Award Winners

NSDL launches 'Chalo, School Chale' campaign across India

Singapore's largest HRTech Marketplace expands to India

Growth in Cyber Attacks Boosts Global Demand for Endpoint Security

Global Ground Station Services Market to be Transformed by Innovative Business Models

Businesses Winning Women's Hearts to Thrive: 9 Mega Trends Leading the Way in the Sheconomy

Berge Bulk vessel to sail with WindWings in 2023

Zerocap enables trade of tokenised carbon credits with A$DC

Razorpay Trusts Purple Quarter to Onboard Ex-Amazon Techie as the CTO

Nanoprecise Sci Corp achieves SOC 1 Type II and SOC 2 Type II Compliance

Rocketium integrates with MoEngage to enable dynamic visual content at scale across channels

Pantum Launches New 3-in-1 Monochrome Laser Printer Series M7310 with Enhanced Connectivity and Printing Capability

FIDO Alliance Announces the FIDO Developer Challenge - India

Tredence Wins Databricks 2022 Retail and CPG Partner of the Year Award

Pro Music Rights, Inc., one of the world's largest music licensing companies, announces the closing of an undisclosed funding round of $5,500,000 USD and a valuation of $422,583,333 USD

Timecho, Founded by the Creators of Apache IoTDB, Raises Over US$10 Million First Fund for Open-Source Software R&D and Time-Series Database Solutions

Regional Center Lawsuits Receive Favorable Preliminary Injunction Ordering the Immediate Start of the EB-5 Regional Center Program

Carl's Jr. Australia Announces Partnership with UFC

MYLE VAPE WINS "BEST BRAND" AWARD AT THE 2022 MENA VAPE AWARDS

WDO names Patricia Moore as recipient of 2022 World Design Medalâ„¢

Databricks Unveils New Innovations for its Industry Leading Data Lakehouse Platform

Databricks Announces Major Contributions to Flagship Open Source Projects at Data + AI Summit

NewAmsterdam Pharma and the Menarini Group Sign Licensing Deal to Commercialize Obicetrapib in Europe

Ascend brings new EV, battery materials to Battery Show Europe

PokerStars officially launches in hometown Ontario

Kensing Announces Acquisition of Vitae Naturals

stern magazine exclusive: Henry Kissinger argues against a coup against Putin: "It is likely that a peace agreement will have to be made with Putin" - but the West should not "tolerate" a Russian nuclear threat

Mr. Cook to launch small home appliances and also large-sized pressure cookers at Vibrant India 2022

Elton John Gifts Hard Rock International His One-of-a-Kind Gucci Suit in Exchange for His Legendary Dodger's Uniform Amid Headlining American Express presents BST Hyde Park

4th Edition of WTCA Prime Office Index LatAm Proves Projections for the Premium Office Segment Are Increasingly Positive in Latin America

INX and SICPA Sign a Groundbreaking Memorandum of Understanding To Establish a Joint Venture to Develop An Innovative Central Bank Digital Currency Ecosystem To Support Monetary Sovereignty

Talogy launches modular assessment solutions, bringing first-of-its-kind configurability to the market

ICFAI Business School (IBS) Offering Scholarship Program worth 10 Crores to Students

Ariel and Hoerbiger Announce Partnership for Non-Lube Compressor Solutions for Hydrogen Mobility Markets

Glenmark Pharmaceuticals Inc., USA continues to expand its Over-The-Counter (OTC) Portfolio with the acquisition of approved ANDAs from Wockhardt Limited

Cendyn announces partnership with OpenTable to integrate hotel reservation and dining data into a unified guest profile

Lifestyle announces its most-awaited SALE of the Season

New hope for IVF patients as global study published in Human Reproduction shows AI can effectively assess genetic integrity of embryos

Altair Releases Altair Unlimited Data Analytics Appliance

Gotion High-Tech intends to invest in a production base in Europe with an annual production capacity of 18GWh

Mass production of new-generation 430W Vertex S begins, Trina Solar is delivering the ultra-high performance modules for all rooftops

BEQUANT launches industry-first DeFi platform for institutional clients

Clarivate Names World's Leading Journals with the 2022 Journal Citation Reports

Rupa Publications India launches 'The 10 Gunas' book by Prof. PR Mukund

Argentine President Fernandez meet with Gotion High-tech chairman Li Zhen

Bharath Institute of Higher Education and Research wins award at UK's iconic House of Commons, plans to help 100 deserving underprivileged children from TN pursue research overseas

Dukaan Partners with SHIELD to Strengthen Security and Elevate User Trust for Millions

Books on Prime Minister Narendra Modi's relationship with the Sikh community internationally released by NID Foundation at Chicago

Anand Rathi creates an industry-first rap-based ad campaign for investor education

Culture: The Department of Culture and Tourism - Abu Dhabi and UNESCO launch a new report on the economic impact of COVID-19: Pandemic cost culture up to 40% in lost revenue and over 10 million jobs

ICRA upgrades Outlook to Stable, while re-affirming long-term rating of Edelweiss Financial Services

EZVIZ LAUNCHES C1C-B, A COMPACT INDOOR WiFi CAMERA WITH SUPERIOR SAFETY QUALITY

Help Save Lives With Heads Up! Helmet Safety Campaign

HOLBORN DOUBLES DOWN ON INTERNATIONAL EXPANSION

FMC launches pre-emergent herbicide to support sugarcane farmers in India

Dawid Malan, Fateh Education's Brand Ambassador bats for children from KHUSHII NGO

Ceres and Shell announce electrolyser agreement for green hydrogen

DSM-Firmenich update on public exchange offer process

Transforming Education for the Real-world: No subjects, no classrooms, no exams

CJ 4DPLEX, Cines Filmax Adds 4DX Auditorium to Gran Via Location

Wemade's MMORPG masterpiece, MIR4, to reveal new PVP content - Bicheon Heist

ST Telemedia Global Data Centres (Thailand) Earns Frost & Sullivan's 2022 Competitive Strategy Leadership Award in the Data Center Colocation Services Market

Asia businesses struggle to offset losses from increased B2B bad debt, Atradius survey reveals

Pijar Foundation and EdHeroes Network Strategic Agreement: Global Future Talent Alliance and EdHeroes Hub

Omnicom Media Group Heads Home from Cannes with 39 Lions, the Media Network Crown, a New Global Consultancy and a Big Lead in Connected Commerce

Amai Proteins, producer of 100% protein sweetener that reduces sugar in Food & Beverages by up to 70%, voted Global Winner at the 2022 Extreme Tech Challenge Competition

NEOM and McLaren Racing announce strategic title partnership to drive innovation and talent development in electric motorsport

IAS Announces Campaign Sync Solution with Xandr's Invest DSP to Match Advertisers' Pre- and Post-bid Settings

Shahani Group Chairperson Mrs Maya Shahani Featured in The Knowledge Review's 2022 Listing of India's Most Admired Women in the Education Sector

Court Lifts Final Injunction in Favor of Altair in World Programming Case

Medvarsity partners with McGraw Hill to augment its courses and improve learning outcomes

PHD Media and 1862 OML win big at the Inkspell Media's MarTech Fest held on 24th June in New Delhi

Sigmoid strengthens financial services, industrial, and media offerings with accelerators and hiring deep domain experts

Thailand Draws on Creativity, Technology to Answer Consumer Demand for Eco-Friendly Lifestyle Goods

JOYSBIO offers SARS-COV-2 Antigen Rapid Test that detects Omicron subvariants BA.4 and BA.5

Global Secure SD-WAN Solutions Thrive as Organizations Turn to Cloud and 5G

Top 3 Countries for Future Growth Potential: The United States, Norway, and the United Kingdom

Abcam: Appointment of Vice President of Investor Relations

LIXIL announces winners and continuing support of the Asia Pacific Property Awards 2022-23

The 7th edition of the Embedded Safety & Security Summit culminated with a triumph

CSM Tech wins IMC Awards for transformation at JSW mines

Myntra StyleCast rolls out Campus Ambassador Program, kick starting the journey for ~500 aspiring young creators from leading colleges

12th DBN Science and Technology Award Ceremony to Further Broaden the Vision of Agricultural Innovation

Petal Search wins iF Award 2022, signaling its dedication to next-generation search engine

Hisense Praises Women Football Players through #RememberTheName Campaign, Commits to Enhancing Tournament Experience

CGTN: Why China's development philosophy can help promote global prosperity

Theme song "We Will Be Better" echoes 25th anniversary of HK's return to motherland

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Mumbai metro line 3 cannot start until c...
Despite censure, Trinamool MLA sticks to...
ED grills Sanjay Raut for 10 hours in mo...
AAP joins protest of Bengaluru civic bod...
Centre warns edtech companies against un...
Ordered trust vote in Maha, slammed Nupu...
More...    
 
 Top Stories
ISL: Bengaluru FC sign youngsters A... 
Litigations against fossil fuel ind... 
Rath Yatra was targeted in Congress... 
Manipur landslide: 21 bodies found,... 
Sudesh Bhosale, DJ Sheizwood spin a... 
After London Indian Film Festival, ... 
1st ODI: Deepti Sharma's all-round ... 
Headache most reported Covid sympto...